Discovering the true signals of disease to power life-changing drugs.
Public company, workplace, funding, and market signals
Founders
Chief Strategy Officer at Spellbook; former Co-founder and CEO of Sequence Bio
Founder & CEO
Investors
Sequence Bio · Jun 2026
Sequence Bio announced a brand refresh reflecting its evolution toward in-house target identification and validation science and a broader discovery pipeline.
Sequence Bio · Dec 2024
Sequence Bio entered a research collaboration with Memorial University to study familial multiple sclerosis in Newfoundland and Labrador, aiming to identify novel drug targets.
Sequence Bio · Sep 2023
Sequence Bio named Lynn Healey CEO, promoting her from Chief Operating and Financial Officer.
PR Newswire · Apr 2022
Sequence Bio announced a three-year discovery collaboration with LEO Pharma to use its platform for multi-omic analysis and dermatology target discovery.
Sequence Bio · Aug 2019
Sequence Bio disclosed receiving investment from Y Combinator and participating in YC Demo Day, expanding its founder and investor network.